ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

read more

ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer

Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]

read more

ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

Long-term follow-up data from the CheckMate-214 study of the nivolumab plus ipilimumab combination in untreated, advanced clear cell kidney cancer patients were presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. Patients were followed for at least 4 years after treatment with nivolumab plus ipilimumab […]

read more

ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer

Data from the CheckMate-920 study on the safety and effectiveness of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) was presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. CheckMate-920 is a community-based, phase IIIb/IV clinical trial of nivolumab plus […]

read more

ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. In this study, the results of which will be presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) […]

read more

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]

read more

Summary from ASCO 2020 virtual meeting

This article nicely summarises the most exciting research highlights from the ASCO 2020 Virtual Scientific Programme which demonstrate the evolution of treatments for advanced renal cell carcinoma (RCC), with a focus on combination treatments, salvage therapies and treatments for non-clear cell RCC. Read the review article in the Journal of Clinical Oncology here

read more

ASCO 2020: Lenvatinib plus pembrolizumab for disease progression after immunotherapy for metastatic kidney cancer

Results from a phase II trial of a combination of lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) which was not responding to treatment with immune checkpoint inhibitor therapy was presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend. One hundred and four (104) patients […]

read more

ASCO 2020: Subtypes of kidney cancer differ in sites of metastases

A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]

read more

ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer

Results from the phase II FRACTION-RCC clinical trial to assess the nivolumab plus ipilimumab combination in previously treated advanced renal cell carcinoma (RCC) patients were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. The study looked at 46 patients with previously treated RCC that was not responding to […]

read more
Showing 11 to 20 of 43 results
  TOP